As Global Head of R&D, Rossetti leads the strategy for Merck’s discovery and development efforts in Healthcare. He joined Merck in July, 2014, and has since led the acceleration of several key programs through the pipeline, with two FDA approvals for the company’s immune-checkpoint inhibitor BAVENCIO® (avelumab (anti-PDL1)) in Merkel cell carcinoma and urothelial carcinoma, as well as marketing authorization in Europe for MAVENCLAD™ (Cladribine Tablets) in multiple sclerosis. He has also advanced the innovation of Merck’s discovery teams into development, including anti-PDL1-TGFbeta-trap and BTK inhibitor. Under his leadership, Merck Healthcare R&D has been transformed, with significant potential to deliver the scientific, clinical, regulatory and medical excellence of its teams to patients in need.
Before joining Merck, Rossetti served as Senior Vice President, responsible for Global Scientific Strategy and Late Stage Development at Merck Sharp & Dohme, or MSD. In the latter position, he was responsible for clinical development from Phase II to Phase V across all therapeutic areas.
Prior to joining MSD in 2006, Rossetti spent 18 years in academia during which he had considerable involvement with the pharmaceutical industry in both discovery and development. In his latest assignment, he was Professor of Medicine and led the Diabetes Research & Training Center at the Albert Einstein College of Medicine.
Rossetti has authored more than 150 peer-reviewed scientific journals. He is a Post-Doctoral Fellow of Rome University Medical School and of Yale University Medical School. He holds a Doctorate in Medicine from the Trieste University Medical School, Italy.